Nielsen, Lene Musfelt
Hauge, Maria Guldbrandt
Ersbøll, Anne S.
Johansen, Marianne
Linde, Jesper James
Damm, Peter
Nielsen, Karoline Kragelund
Article History
Received: 13 May 2022
Accepted: 13 October 2022
First Online: 11 November 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and recommendations. This study recruited participants from the CPH-PRECIOUS study, which has received ethics approval from the Capital Region’s Committee on Biomedical Research Ethics (H-18065695). The CPH-PRECIOUS participants, who were contacted regarding the qualitative study, had all signed an informed consent form in advanced agreeing to be contacted for further investigations. Women who participated in the qualitative study provided additional written informed consent for this study. Furthermore, to ensure the anonymity of participants, they are presented with the use of pseudonyms in this article.
: Not applicable.
: KKN is employed at Steno Diabetes Center Copenhagen, a public hospital and research institution under the Capital Region of Denmark, which is partly funded by a grant from the Novo Nordisk Foundation. ASE has been employed by Novo Nordisk A/S after the CPH-PRECIOUS study was designed and funded. Novo Nordisk A/S is not involved in this project. LMN, MGH, MJ, JLL and PD declare no conflicts of interest.